Effect of capsule 'UB03' containing potential probiotic strains for the treatment of patients with irritable bowel syndrome

The objective of this research was to study the efficacy and safety of capsule 'UB03' to treat patients with Irritable Bowel Syndrome (IBS). Thirty patients with Rome II IBS were assigned to receive capsule 'UB03' (10 billion lyophilised bacteria and yeast/capsule produced by Unique Biotech Limited, India) twice daily for 90 days. Assessment of IBS was carried out according with Rome II criteria and their severity for 90 days of treatment with an interval of 30 days. Complete haemogram, serum glutamic pyruvic transaminase, serum creatinine were performed as a part of safety evaluation at the time of inclusion and after 90 days of treatment. There was significant improvement in frequency of defecation (23%), consistency of stool, abdominal discomfort, bloating and flatulence. However, there was no significant change in abdominal pain and mucus in stool. This trial demonstrates that the consumption of capsule 'UB03' containing potential probiotic strains is found to be effective and safe for the treatment of patients with IBS.

Download Full-text

How restrictive are Rome II criteria for the diagnosis of the irritable bowel syndrome (IBS)?

Gastroenterology ◽

10.1016/s0016-5085(01)81147-1 ◽

2001 ◽

Vol 120 (5) ◽

pp. A231-A231

Author(s):

F MEARIN ◽

X BADIA

Keyword(s):

Irritable Bowel Syndrome ◽

Rome Ii Criteria ◽

Irritable Bowel

Download Full-text

Faculty Opinions recommendation of Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717958672.793516776 ◽

2016 ◽

Author(s):

Robin Spiller

Keyword(s):

Irritable Bowel Syndrome ◽

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Irritable Bowel

Download Full-text

Faculty Opinions recommendation of Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.727355494.793536320 ◽

2017 ◽

Author(s):

Adam Farmer

Keyword(s):

Irritable Bowel Syndrome ◽

Phase 2 ◽

Efficacy And Safety ◽

Irritable Bowel

Download Full-text

A commentary on “The efficacy and safety of probiotics for patients with constipation predominant irritable bowel syndrome: A systematic review and meta-analysis based on seventeen randomized controlled trials” [Int. J. Surg. 2020; 79: 111–119]

International Journal of Surgery ◽

10.1016/j.ijsu.2021.105993 ◽

2021 ◽

pp. 105993

Author(s):

Guanhua Rao ◽

Zhijian Meng

Keyword(s):

Systematic Review ◽

Irritable Bowel Syndrome ◽

Randomized Controlled Trials ◽

Meta Analysis ◽

Controlled Trials ◽

Efficacy And Safety ◽

Randomized Controlled ◽

Irritable Bowel

Download Full-text

PWE-056 Prospective evaluation of 403 patients with diarrhoea predominant irritable bowel syndrome (D-IBS) fulfilling Rome II criteria: Abstract PWE-056 Table 1

Gut ◽

10.1136/gutjnl-2012-302514d.56 ◽

2012 ◽

Vol 61 (Suppl 2) ◽

pp. A319.2-A320 ◽

Cited By ~ 1

Author(s):

S Lin ◽

M Kurien ◽

J S Leeds ◽

D S Sanders

Keyword(s):

Irritable Bowel Syndrome ◽

Prospective Evaluation ◽

Rome Ii Criteria ◽

Irritable Bowel

Download Full-text

EFFICACY AND SAFETY OF INTESTINAL SECRETAGOGUES FOR CHRONIC CONSTIPATION: A SYSTEMATIC REVIEW AND META-ANALYSIS

Arquivos de Gastroenterologia ◽

10.1590/s0004-2803.201800000-41 ◽

2018 ◽

Vol 55 (suppl 1) ◽

pp. 2-12 ◽

Cited By ~ 4

Author(s):

Juan Sebastian LASA ◽

María Josefina ALTAMIRANO ◽

Luis Florez BRACHO ◽

Silvina PAZ ◽

Ignacio ZUBIAURRE

Keyword(s):

Irritable Bowel Syndrome ◽

Chronic Constipation ◽

Meta Analysis ◽

Efficacy And Safety ◽

Spontaneous Bowel Movement ◽

Intention To Treat ◽

Mesh Terms ◽

Bowel Movements ◽

Irritable Bowel ◽

Therapeutic Alternatives

ABSTRACT BACKGROUND: Intestinal secretagogues have been tested for the treatment of chronic constipation and constipation-predominant irritable bowel syndrome. The class-effect of these type of drugs has not been studied. OBJECTIVE: To determine the efficacy and safety of intestinal secretagogues for the treatment of chronic constipation and constipation-predominant irritable bowel syndrome. METHODS: A computer-based search of papers from 1966 to September 2017 was performed. Search strategy consisted of the following MESH terms: intestinal secretagogues OR linaclotide OR lubiprostone OR plecanatide OR tenapanor OR chloride channel AND chronic constipation OR irritable bowel syndrome. Data were extracted as intention-to-treat analyses. A random-effects model was used to give a more conservative estimate of the effect of individual therapies, allowing for any heterogeneity among studies. Outcome measures were described as Relative Risk of achieving an improvement in the symptom under consideration. RESULTS: Database Search yielded 520 bibliographic citations: 16 trials were included for analysis, which enrolled 7658 patients. Twelve trials assessed the efficacy of intestinal secretagogues for chronic constipation. These were better than placebo at achieving an increase in the number of complete spontaneous bowel movements per week [RR 1.87 (1.24-2.83)], at achieving three or more spontaneous bowel movements per week [RR 1.56 (1.31-1.85)] and at inducing spontaneous bowel movement after medication intake [RR 1.49 (1.07-2.06)]. Similar results were observed when assessing the efficacy of intestinal secretagogues on constipation-predominant irritable bowel syndrome based on the results of six trials. CONCLUSION: Intestinal secretagogues are useful and safe therapeutic alternatives for the treatment of constipation-related syndromes.

Download Full-text